pyrazolone

 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2014
2014
Amyotrophic lateral sclerosis (ALS) is a progressive and ultimately fatal neurodegenerative disease. Pyrazolone containing small… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 1
  • figure 4
Is this relevant?
Highly Cited
2010
Highly Cited
2010
The histone acetyltransferase (HAT) p300/CBP is a transcriptional coactivator implicated in many gene regulatory pathways and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
  • figure 5
Is this relevant?
2010
2010
Interruption of TGFbeta signaling through inhibition of the TGFbetaR1 kinase domain may prove to have beneficial effect in both… (More)
Is this relevant?
2009
2009
Two series of novel rigid pyrazolone derivatives were synthesized and evaluated as inhibitors of Mycobacterium tuberculosis (MTB… (More)
Is this relevant?
2006
2006
The risk of agranulocytosis associated with the use of pyrazolone drugs at therapeutical doses and for short periods of time has… (More)
  • figure 1
  • table 1
  • figure 2
  • figure 3
  • table 2
Is this relevant?
Highly Cited
2003
Highly Cited
2003
BACKGROUND Propyphenazone (1,2-dihydro-1,5-dimethyl-4-(1-methylethyl)-2-phenyl-3H-pyrazol-3-one; PP) is a nonsteroidal anti… (More)
Is this relevant?
1999
1999
Pyrazolone drug hypersensitivity (PDH) may manifest as angioedema, urticaria, and/or life threatening anaphylactic shock… (More)
Is this relevant?
1998
1998
BACKGROUND In sensitive patients pyrazolone drugs can precipitate adverse reactions ranging from urticaria and angioedema to… (More)
Is this relevant?
Review
1986
Review
1986
In many countries, the pyrazolone derivatives, which include dipyrone, antipyrine, aminopyrine and propyphenazone, are widely… (More)
  • figure 1
  • figure 2
  • figure 3
  • table I
  • table II
Is this relevant?
1981
1981
Studies carried out in 68 patients with idiosyncratic reactions to noramidopyrine and/or aminophenazone led to distinction of two… (More)
Is this relevant?